Ionis Pharmaceut (IONS)

$30.25 0.90 (2.97%)

20:00 EDT IONS Stock Quote Delayed 30 Minutes

The 3 Most Undervalued Pharma Stocks to Buy in May 2024

By Viktor Zarev, InvestorPlace Contributor May 9, 2024

Investors looking for good deals in the pharmaceutical industry should watch out for these three undervalued pharma stocks.

IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024

3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies

The 7 Most Hated Stocks by Institutional Traders

Volume:

Previous Close $31.72

Market Cap 4.95B

PE Ratio -9.96

EPS -3.0365

Volume (Avg. Vol.) 837,700

Day's Range $30.80 - $31.58

52-Week Range $30.23 - $52.34

Dividend & Yield N/A (N/A)

IONS Stock Predictions, Articles, and Ionis Pharmaceut News

3 Biotech Stocks to Sell Before They’re 6 Feet Under

By John Blankenhorn, InvestorPlace Contributor Apr 24, 2023

Biotech stocks with no earnings, no cash, and no path to profit will have no chance at survival. Here's three such biotech stocks to avoid.

3 Biotech Stocks to Sell in October

By Muslim Farooque, InvestorPlace Contributor Sep 29, 2022

These biotech stocks to sell are at a cross roads with their businesses with few growth catalysts ahead amid this turbulent market.

The 7 Best Biotech Stocks to Buy

By Dana Blankenhorn, InvestorPlace Contributor Sep 20, 2022

The best biotech stocks to buy are a lot like the best computer stocks 40 years ago; the biggest similarity is how hard they are to predict.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

By William White, InvestorPlace Writer Jul 29, 2022

Good morning, trader! It's time to start off Friday with a breakdown of the biggest pre-market stock movers traders need to know about!

5 Cathie Wood Stocks to Buy in June

By Tezcan Gecgil, InvestorPlace Contributor Jun 9, 2022

Despite the recent selloff, these five Cathie Wood stocks are likely to bounce back thanks to their focus on impressive innovation.

7 Potential Biotech Stocks Buyout Targets in 2022

By Shanthi Rexaline Apr 21, 2022

Big biopharma companies usually rely on M&A to get immediate access to a new class of drug or technology, fill in the gap in their pipeline and compensate for revenue loss from patent expiration of blockbuster products.

7 F-Rated Stocks to Avoid for the Rest of 2021

By Louis Navellier and the InvestorPlace Research Staff Aug 2, 2021

In a churning market like this, you want to steer clear of stocks that are floundering. Here are sevens stocks to avoid today.

DDD, AONE, RAVN, ION: 4 Stocks That Cathie Wood’s ARK Funds Are Betting On Today

By William White, InvestorPlace Writer Mar 24, 2021

Cathie Wood's Ark Invest continues to add more shares to its holdings with it picking out a few companies worth noting on Wednesday.

7 Unhealthy Biotech Stocks To Sell Before They Sicken Your Portfolio

By Louis Navellier and the InvestorPlace Research Staff Oct 23, 2020

It’s a good time to separate the weak from the strong.

Akcea Therapeutics News: AKCA Stock Rockets on Pfizer Licensing Deal

By William White, InvestorPlace Writer Oct 7, 2019

Akcea Therapeutics (AKCA) stock is flying high on Monday following news of a $250 million deal with Pfizer (NYSE:PFE) for licensing rights.

Credit Suisse Absolutely Is Right to Double Down on Pfizer Stock

By James Brumley, InvestorPlace Feature Writer May 20, 2019

Buy Pfizer stock on this current round of weakness. The underpinnings are bullish for 2020 and beyond.

7 A-Rated Healthcare Stocks for Industry Expansion

By Louis Navellier, Editor, Growth Investor May 20, 2019

These healthcare stocks will help you not only profit from the growing demand, but also the growing tech in the healthcare sector.

5 Stocks to Sell as They Climb to New Highs

By Will Healy, InvestorPlace Contributor Apr 11, 2019

These stocks to sell have rewarded investors during the bull market, but are vulnerable if the market experiences a sustained downturn.

6 of the Most Expensive Stocks That Could Go On Sale

By Will Healy, InvestorPlace Contributor Mar 8, 2019

Although these equities have made the most expensive stocks list, increasing competition poses a threat to their elevated multiples.

5 Pharma Stocks to Stay Away From

By Will Healy, InvestorPlace Contributor Nov 12, 2018

With an aging population, pharma stocks can be a very profitable investments. These 5 biotechs probably aren't.

Why Every Investor Should Hold Shares of Biogen Stock

By Chris Lau, InvestorPlace Contributor Jul 25, 2018

Biogen reported solid study results for its Alzheimer's study and followed up with a solid quarterly earnings report. BIIB stock is a clear core holding for investors.

10 Ionis Pharmaceuticals Inc Earnings Highlights

By William White, InvestorPlace Writer May 4, 2018

Ionis Pharmaceuticals (IONS) released its earnings report for the first quarter of 2018 on Friday and 'InvestorPlace' has some highlights from it.

9 More Stocks Still Growing Faster Than Amazon

By James Brumley, InvestorPlace Feature Writer Jan 2, 2018

If you're looking for growth, Amazon.com isn't your only investment choice. These names are on a tear as well, and could be worthy additions to your portfolio.

Ionis Pharmaceuticals Inc (IONS) Shares Fall on Drug Safety Concerns

By William White, InvestorPlace Writer May 15, 2017

Ionis Pharmaceuticals (IONS) stock was down on Monday on safety concerns for its drug inotersen following results from a phase 3 study.

Ionis Pharmaceuticals Inc (IONS) Stock Dips on Goldman Sachs Downgrade

By Karl Utermohlen, InvestorPlace Writer Mar 10, 2017

Ionis Pharmaceuticals (IONS) shares were plummeting Friday as the stock received a downgrade from Goldman Sachs following its disastrous Monday.

Ionis Pharmaceut (IONS)

The 3 Most Undervalued Pharma Stocks to Buy in May 2024

IONS Stock Earnings: Ionis Pharmaceuticals Beats EPS, Misses Revenue for Q1 2024

3 Stocks to Buy Now Before They Become Tomorrow’s Trillion-Dollar Companies

The 7 Most Hated Stocks by Institutional Traders

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

Ionis Pharmaceut (IONS)

Louis Navellier's Total Grade

Is ? a BUY?

Louis Navellier's Total Grade

Louis Navellier's Total Grade

Fundamental Grade

Quantitative Grade

IONS Stock Predictions, Articles, and Ionis Pharmaceut News

Subscriber Sign in